Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
暂无分享,去创建一个
Ana Lluch | A. Lluch | P. Eroles | A. Bosch | J. Pérez-Fidalgo | Ana Bosch | Pilar Eroles | J Alejandro Pérez-Fidalgo
[1] A. Lluch,et al. Mechanisms of resistance to hormonal treatment in breast cancer , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[2] J. Bergh,et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. A. Carter,et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group , 2012 .
[4] Y. Im,et al. Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere') , 2010 .
[5] S. Loi,et al. Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[6] E. Mamounas,et al. Tamoxifen Use , and Outcomes in Women With Estrogen Receptor – Positive Early-Stage Breast Cancer , 2003 .
[7] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[8] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[9] C. Perou,et al. Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. , 2009 .
[10] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[11] E. Winer,et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Y. Shyr,et al. Transforming Growth Factor-β Signaling–Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion , 2008, Molecular Cancer Research.
[13] R. Gelber,et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.
[14] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] B. Turk,et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.
[16] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[17] Funda Meric-Bernstam,et al. Metformin: a therapeutic opportunity in breast cancer , 2010 .
[18] L. Lagasse,et al. Origin of Serum Estradiol in Postmenopausal Women , 1982, Obstetrics and gynecology.
[19] D. McDonald,et al. Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.
[20] Nicholas J. Wang,et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.
[21] K Miller,et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[23] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] L. Helman,et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism , 2007, Oncogene.
[25] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[27] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] John W M Martens,et al. Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.
[29] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[30] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[31] Yuan Qi,et al. Multifactorial approach to predicting resistance to anthracyclines. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[33] J. O’Shaughnessy,et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer , 2007 .
[34] J. Baselga. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. , 2011, The oncologist.
[35] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[36] J. Baselga,et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Foekens,et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[39] Kevin Struhl,et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.
[40] L. Chodosh,et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation , 2007, Oncogene.
[41] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] F. Peruzzi,et al. The IGF‐1 receptor in cancer biology , 2003, International journal of cancer.
[43] A. Ashworth,et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.
[44] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[45] J. Thigpen. Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer , 2011 .
[46] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.
[47] R. Gelber,et al. Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer , 2010 .
[48] J. Cuzick,et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Baselga,et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. , 2010 .
[50] V. Beral,et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study , 2007, BMJ : British Medical Journal.
[51] Johan Staaf,et al. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[53] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[54] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[55] Xian Zhou,et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[57] P. Conte,et al. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. , 2009, The oncologist.
[58] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] C. Sotiriou,et al. Gene profiling assay and application: the predictive role in primary therapy. , 2011, Journal of the National Cancer Institute. Monographs.
[60] Z. C. Fonfach,et al. Clasificación molecular del cáncer de mama , 2011 .
[61] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[62] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[63] J. Lubiński,et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Wei Wang,et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.
[65] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[66] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[67] C. Perou,et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.
[68] Charles M. Perou,et al. Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.
[69] Alberto Costa,et al. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer , 2010, Breast Cancer Research and Treatment.
[70] D. Miles,et al. Abstract P6-12-03: Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC) , 2010 .
[71] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[72] Harry Bartelink,et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.
[73] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[74] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[75] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[76] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[77] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[78] J. Dixon,et al. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer , 2010, Breast Cancer Research and Treatment.
[79] R. Gray,et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). , 2010 .
[80] Suzanne F. Jones,et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] D. Hardie,et al. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy , 2007, Nature Reviews Molecular Cell Biology.
[82] C. Sotiriou,et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.
[83] Arlene Chan,et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] A. Lluch,et al. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. , 2010, Cancer treatment reviews.
[85] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[86] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[87] A. Schneeweiss,et al. Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial , 2010 .
[88] P. Siiteri. Adipose tissue as a source of hormones. , 1987, The American journal of clinical nutrition.
[89] B. Kemp,et al. AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling , 2007, Circulation research.
[90] Funda Meric-Bernstam,et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[92] C. Perou,et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer , 2008 .